Cargando…

The effect of sarcopenia and sarcopenic obesity on survival in gastric cancer

BACKGROUND: Sarcopenic obesity arises from increased muscle catabolism triggered by inflammation and inactivity. Its significance lies in its role in contributing to morbidity and mortality in gastric cancer. This study aims to explore the potential correlation between sarcopenia, sarcopenic obesity...

Descripción completa

Detalles Bibliográficos
Autores principales: Şahin, Muzaffer Ece Hakan, Akbaş, Feray, Yardimci, Aytul Hande, Şahin, Eren
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10537530/
https://www.ncbi.nlm.nih.gov/pubmed/37770828
http://dx.doi.org/10.1186/s12885-023-11423-y
_version_ 1785113124648517632
author Şahin, Muzaffer Ece Hakan
Akbaş, Feray
Yardimci, Aytul Hande
Şahin, Eren
author_facet Şahin, Muzaffer Ece Hakan
Akbaş, Feray
Yardimci, Aytul Hande
Şahin, Eren
author_sort Şahin, Muzaffer Ece Hakan
collection PubMed
description BACKGROUND: Sarcopenic obesity arises from increased muscle catabolism triggered by inflammation and inactivity. Its significance lies in its role in contributing to morbidity and mortality in gastric cancer. This study aims to explore the potential correlation between sarcopenia, sarcopenic obesity, and gastric cancer, as well as their effect on survival. MATERIALS AND METHODS: This retrospective study included 162 patients aged ≥ 18 years who were diagnosed with stomach cancer. Patient age, gender, diagnostic laboratory results, and cancer characteristics were documented. Sarcopenia was assessed using the skeletal muscle index (SMI) (cm2/m2), calculated by measuring muscle mass area from a cross-sectional image at the L3 vertebra level of computed tomography (CT). RESULTS: Among the 162 patients, 52.5% exhibited sarcopenia (with cut-off limits of 52.4 cm2/m2 for males and 38.5 cm2/m2 for females), and 4.9% showed sarcopenic obesity. Average skeletal muscle area (SMA) was 146.8 cm2; SMI was 50.6 cm2/m2 in men and 96.9 cm2 and 40.6 cm2/m2 in women, respectively. Sarcopenia significantly reduced mean survival (p = 0.033). There was no association between sarcopenic obesity and mortality (p > 0.05), but mortality was higher in sarcopenic obesity patients (p = 0.041). Patient weight acted as a protective factor against mortality, supporting the obesity paradox. Tumor characteristics, metabolic parameters, and concurrent comorbidities did not significantly impact sarcopenia or mortality. CONCLUSION: Sarcopenia is more prevalent in the elderly population and is linked to increased mortality in gastric cancer patients. Paradoxically, higher body mass index (BMI) was associated with improved survival. Computed tomography offers a practical and reliable method for measuring muscle mass and distinguishing these distinctions. TRIAL REGISTRATION: This study was approved by Istanbul Training and Research Hospital Clinical Research Ethics Committee of the University of Health Sciences (29.05.2020/2383).
format Online
Article
Text
id pubmed-10537530
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-105375302023-09-29 The effect of sarcopenia and sarcopenic obesity on survival in gastric cancer Şahin, Muzaffer Ece Hakan Akbaş, Feray Yardimci, Aytul Hande Şahin, Eren BMC Cancer Research BACKGROUND: Sarcopenic obesity arises from increased muscle catabolism triggered by inflammation and inactivity. Its significance lies in its role in contributing to morbidity and mortality in gastric cancer. This study aims to explore the potential correlation between sarcopenia, sarcopenic obesity, and gastric cancer, as well as their effect on survival. MATERIALS AND METHODS: This retrospective study included 162 patients aged ≥ 18 years who were diagnosed with stomach cancer. Patient age, gender, diagnostic laboratory results, and cancer characteristics were documented. Sarcopenia was assessed using the skeletal muscle index (SMI) (cm2/m2), calculated by measuring muscle mass area from a cross-sectional image at the L3 vertebra level of computed tomography (CT). RESULTS: Among the 162 patients, 52.5% exhibited sarcopenia (with cut-off limits of 52.4 cm2/m2 for males and 38.5 cm2/m2 for females), and 4.9% showed sarcopenic obesity. Average skeletal muscle area (SMA) was 146.8 cm2; SMI was 50.6 cm2/m2 in men and 96.9 cm2 and 40.6 cm2/m2 in women, respectively. Sarcopenia significantly reduced mean survival (p = 0.033). There was no association between sarcopenic obesity and mortality (p > 0.05), but mortality was higher in sarcopenic obesity patients (p = 0.041). Patient weight acted as a protective factor against mortality, supporting the obesity paradox. Tumor characteristics, metabolic parameters, and concurrent comorbidities did not significantly impact sarcopenia or mortality. CONCLUSION: Sarcopenia is more prevalent in the elderly population and is linked to increased mortality in gastric cancer patients. Paradoxically, higher body mass index (BMI) was associated with improved survival. Computed tomography offers a practical and reliable method for measuring muscle mass and distinguishing these distinctions. TRIAL REGISTRATION: This study was approved by Istanbul Training and Research Hospital Clinical Research Ethics Committee of the University of Health Sciences (29.05.2020/2383). BioMed Central 2023-09-28 /pmc/articles/PMC10537530/ /pubmed/37770828 http://dx.doi.org/10.1186/s12885-023-11423-y Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Şahin, Muzaffer Ece Hakan
Akbaş, Feray
Yardimci, Aytul Hande
Şahin, Eren
The effect of sarcopenia and sarcopenic obesity on survival in gastric cancer
title The effect of sarcopenia and sarcopenic obesity on survival in gastric cancer
title_full The effect of sarcopenia and sarcopenic obesity on survival in gastric cancer
title_fullStr The effect of sarcopenia and sarcopenic obesity on survival in gastric cancer
title_full_unstemmed The effect of sarcopenia and sarcopenic obesity on survival in gastric cancer
title_short The effect of sarcopenia and sarcopenic obesity on survival in gastric cancer
title_sort effect of sarcopenia and sarcopenic obesity on survival in gastric cancer
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10537530/
https://www.ncbi.nlm.nih.gov/pubmed/37770828
http://dx.doi.org/10.1186/s12885-023-11423-y
work_keys_str_mv AT sahinmuzafferecehakan theeffectofsarcopeniaandsarcopenicobesityonsurvivalingastriccancer
AT akbasferay theeffectofsarcopeniaandsarcopenicobesityonsurvivalingastriccancer
AT yardimciaytulhande theeffectofsarcopeniaandsarcopenicobesityonsurvivalingastriccancer
AT sahineren theeffectofsarcopeniaandsarcopenicobesityonsurvivalingastriccancer
AT sahinmuzafferecehakan effectofsarcopeniaandsarcopenicobesityonsurvivalingastriccancer
AT akbasferay effectofsarcopeniaandsarcopenicobesityonsurvivalingastriccancer
AT yardimciaytulhande effectofsarcopeniaandsarcopenicobesityonsurvivalingastriccancer
AT sahineren effectofsarcopeniaandsarcopenicobesityonsurvivalingastriccancer